Minimal GVHD following in-vitro Tcell–depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors

Barge, Renée M. Y.; Osanto, Susanne; Marijt, W.A.F.; Starrenburg, C. W. J.; Fibbe, Willem E.; Nortier, J.W.R.; Falkenburg, J. H. F.; Willemze, R.

doi:10.1016/s0301-472x(03)00200-5

Cited by 44 publications

(40 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 The RIC regimen consisted of fludarabine (30 mg/m 2 , intravenously, days À10 to À6), busulphan (3.2 mg/kg, intravenously, days À6 and À5) and ATG (10 mg/kg/day intravenously, days À4 to À1), for both sibling and matched unrelated donor (MUD) grafts. The MA conditioning regimen consisted of cyclophosphamide (60 mg/ kg/day intravenously for 2 consecutive days) followed by single dose of total body irradiation (TBI, 9 Gy, day À1) in patients receiving sibling donor grafts.…”

Section: Patientsmentioning

confidence: 99%

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Heiden

Kalpoe

Barge

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requiring CMV therapy. In total, 107 consecutive transplant recipients were evaluated. Cytomegalovirus DNA load in plasma was monitored longitudinally; details on antiviral therapy and treatment responses were analyzed retrospectively. Fifty-seven CMV treatment episodes were recorded in 34 patients: 20 with valganciclovir (900 mg twice-daily) and 37 with ganciclovir (5 mg/kg twice-daily). Median CMV DNA load reduction was 0.079 and 0.069 log 10 copies/ml/ day in the ganciclovir and valganciclovir group, respectively. Good response on CMV DNA load (reduction below 3.0 log 10 copies/ml) was observed in 75.7% of ganciclovir and 80.0% of valganciclovir treatment episodes. Severe adverse effects were not observed and CMV-related disease did not occur. However, the percentage of patients receiving erythrocyte transfusion was higher in the group of patients receiving ganciclovir as compared to valganciclovir (41 versus 20%, P ¼ 0.116). In conclusion, pre-emptive treatment with valganciclovir and ganciclovir, led to similar reduction of CMV DNA load. Oral valganciclovir is an attractive and safe alternative for pre-emptive CMV treatment in T-cell-depleted allo-SCT recipients.

show abstract

Section: Patientsmentioning

confidence: 99%

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Heiden

Kalpoe

Barge

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…11 Patients with a relative contraindication for conventional myeloablative allo-SCT (n ¼ 35) received a T-cell depleted allo-SCT following reduced intensity conditioning as described previously. 12 All patients received prophylaxis with cotrimoxazole against Pneumocystis jerovici infections. Surveillance for CMV reactivation was performed by quantitative PCR, and pre-emptive therapy was commenced according to procedures described previously.…”

Section: Patients and Proceduresmentioning

confidence: 99%

Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation

Kalpoe

Kroes

Verkerk

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Detection of Varicella-Zoster virus (VZV) DNA in plasma can facilitate the early recognition of complicated VZV-infection in immunocompromised hosts. The correlation of VZV-DNA in plasma with clinical presentations of VZV-infection and subsequent aciclovir treatment in allogeneic stem cell transplant (allo-SCT) recipients was studied. In 81 consecutive VZV-IgG positive allo-SCT recipients, VZV-DNA was measured at regular time points (1, 2 and 4 months) following allo-SCT and patient records were screened for VZV-related symptoms and aciclovir treatment. Subsequently, possible VZV-cases were studied in detail for the course of VZV-DNA and treatment effects. During the initial screening, VZV-DNA was detectable in seven patients. The survey of VZVrelated symptoms revealed five additional possible VZVcases. In cases where suitable plasma samples were available (10 out of 12), VZV-DNA was present almost simultaneously with the first clinical manifestations. No evidence of a preceding phase detectable by VZV-DNA only could be observed. Treatment with aciclovir was associated with a prompt reduction of VZV-DNA load. Detection of VZV-DNA in plasma in allo-SCT recipients accurately reflected the clinical presentation of VZVinfection and treatment with aciclovir. VZV-DNA detection in plasma of allo-SCT recipients appears clinically relevant as this may support early recognition and therapeutic management of VZV-infections following allo-SCT.

show abstract

“…Initially rat antibodies Campath-1M and Campath-1G, and later the humanized form Campath-1H (alemtuzumab), have been administered in different in vivo and in vitro treatment protocols. [7][8][9][10][11][12] The main technical advantage to using Campath in vitro is its easy applicability, compared to the time-consuming procedure of CD34 selection using an affinity-column. At 30 min after addition of the Campath antibody to the graft, the stem cells are infused into the patient.…”

Section: Introductionmentioning

confidence: 99%

Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience

Barge

Starrenburg

Falkenburg

et al. 2006

Bone Marrow Transplant

View full text Add to dashboard Cite

Minimal GVHD following in-vitro Tcell–depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors

Cited by 44 publications

References 31 publications

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Clinical relevance of quantitative varicella-zoster virus (VZV) DNA detection in plasma after stem cell transplantation

Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath ‘in the bag’ as T-cell depletion: the Leiden experience

Contact Info

Product

Resources

About